Last Updated on: 22nd November 2023, 12:21 pm
Semalytix, a life science startup based in Bielefeld, has announced the launch of PatientGPT, a large language model trained on global patient experience data for the life sciences. This new model is the first of its kind and provides a revolutionary approach to drug development.
The technology has been developed by Semalytix and can replace up to 6 months of research with seconds. It is able to analyse and interpret effects and value estimates of medications based on millions of patient experiences. Additionally, a range of safety measures and anonymization guidelines have been implemented to ensure the protection of sensitive patient data.
Co-founder and Chief Product Officer, Janik Jaskolski, said: “We can not only analyze but also precisely query the effects of any medication based on patient experiences and unmet needs worldwide, down to the smallest detail. By the end of the year, we will have over 50 million patient data points in our patient experience data archive, which our own LLM solution will be tuned with. This allows us to gain exact insights into how people live with diseases and generate crucial new knowledge for patient-focused drug development.”
Prof. Dr. Philipp Cimiano, co-founder and Chief Technology Officer of Semalytix, added: “PatientGPT truly unlocks the huge potential of patient experience data that will help shape new therapies and authentically and continuously answer what patients need most.”
Semalytix’s customers include many of the top 20 pharmaceutical companies worldwide. The technology is expected to dramatically accelerate the speed of therapy development and improve how well new drugs match patients’ needs.
Semalytix was founded in 2015 by managing directors Janik Jaskolski, Philipp Cimiano, and Matthias Hartung and currently employs 25 employees.
Today marks a new era in drug development with the announcement of PatientGPT, a large language model trained on global patient experience data for the life sciences. Developed by Bielefeld-based life science startup Semalytix, the model can replace up to 6 months of research with seconds and is capable of analysing and interpreting effects and value estimates of medications based on millions of patient experiences.
Co-founder and Chief Product Officer, Janik Jaskolski, said: “We can not only analyze but also precisely query the effects of any medication based on patient experiences and unmet needs worldwide, down to the smallest detail. By the end of the year, we will have over 50 million patient data points in our patient experience data archive, which our own LLM solution will be tuned with. This allows us to gain exact insights into how people live with diseases and generate crucial new knowledge for patient-focused drug development.”
Prof. Dr. Philipp Cimiano, co-founder and Chief Technology Officer of Semalytix, added: “PatientGPT truly unlocks the huge potential of patient experience data that will help shape new therapies and authentically and continuously answer what patients need most.”
Semalytix’s customers include many of the top 20 pharmaceutical companies worldwide and the technology is expected to dramatically accelerate the speed of therapy development and improve how well new drugs match patients’ needs.
Semalytix, a Bielefeld-based life science startup, has announced the launch of PatientGPT, a groundbreaking language model that uses supervised machine learning and large language models to provide critical accuracy for the life sciences industry.
The model is capable of analysing and interpreting effects and value estimates of medications based on millions of patient experiences in seconds, a task that would otherwise require up to 6 months of work. It also has access to over 100 million sources in 26 different languages, and can access real-time data.
Janik Jaskolski, co-founder and Chief Product Officer of Semalytix, said: “Our PatientGPT summarises thousands of patient voices and will give you an answer to this question, again and again. Billions of pieces of information about patient-centred experiences reveal entirely new opportunities for therapies and medication.”
Prof. Dr. Philipp Cimiano, co-founder and Chief Technology Officer of Semalytix, added: “We want to dramatically accelerate the speed of therapy development and improve how well new drugs match patients’ burdens. We contribute by making the global patient experience as accessible as possible in a compliant and ethical way.”
Semalytix was founded in 2015 by managing directors Janik Jaskolski, Philipp Cimiano, and Matthias Hartung and currently employs 25 employees. Its customers include many of the top 20 pharmaceutical companies worldwide.
